biostudies-literatureUnknown23(1)Shim TS<h4>Background</h4>Multidrug-resistant tuberculosis (MDR-TB) represents a major public health concern, with an ongoing need for new effective treatments. Bedaquiline is an oral diarylquinoline that has shown encouraging treatment success and culture conversion rates in MDR-TB.<h4>Methods</h4>A South Korean patient registry was set up across 19 centres between 2016 and 2018 for the prospective collection of data from patients with MDR-TB who received either a bedaquiline-containing or a non-bedaquiline-containing regimen. Treatment was at the physician's discretion (bedaquiline use requiring approval by special committee) and was based on patient characteristics, disease status, and local treatment guidelines.<h4>Results</h4>The safety population included 172 patients (88 bedaquiline and 84BMC infectious diseases15https://www.ebi.ac.uk/biostudies/studies/S-EPMC9828359biostudies-literatureA prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea.PMC9828359Mok JPark JThoret-Bauchet FKim HLee SHMao GAlquier LShim TSDavis KPai HKim JHBakare NKwon YSBirmingham EChoi JCfalseA prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea.<h4>Background</h4>Multidrug-resistant tuberculosis (MDR-TB) represents a major public health concern, with an ongoing need for new effective treatments. Bedaquiline is an oral diarylquinoline that has shown encouraging treatment success and culture conversion rates in MDR-TB.<h4>Methods</h4>A South Korean patient registry was set up across 19 centres between 2016 and 2018 for the prospective collection of data from patients with MDR-TB who received either a bedaquiline-containing or a non-bedaquiline-containing regimen. Treatment was at the physician's discretion (bedaquiline use requiring approval by special committee) and was based on patient characteristics, disease status, and local treatment guidelines.<h4>Results</h4>The safety population included 172 patients (88 bedaquiline and 842023-01-01T00:00:00Z2023 Jan2026-06-03T16:49:51.37Z2025-04-04T09:30:45.086ZS-EPMC98283593662443210.1186/s12879-022-07955-6